1. Home
  2. KTF vs AKBA Comparison

KTF vs AKBA Comparison

Compare KTF & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DWS Municipal Income Trust

KTF

DWS Municipal Income Trust

HOLD

Current Price

$8.78

Market Cap

361.2M

Sector

Finance

ML Signal

HOLD

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$0.90

Market Cap

343.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KTF
AKBA
Founded
1988
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
361.2M
343.4M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
KTF
AKBA
Price
$8.78
$0.90
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.67
AVG Volume (30 Days)
233.2K
4.8M
Earning Date
01-01-0001
05-07-2026
Dividend Yield
3.54%
N/A
EPS Growth
N/A
93.94
EPS
0.39
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$22.56
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.63
$0.81
52 Week High
$9.37
$3.22

Technical Indicators

Market Signals
Indicator
KTF
AKBA
Relative Strength Index (RSI) 29.43 39.38
Support Level $8.76 $0.85
Resistance Level $9.25 $1.54
Average True Range (ATR) 0.05 0.06
MACD -0.01 -0.01
Stochastic Oscillator 5.56 22.79

Price Performance

Historical Comparison
KTF
AKBA

About KTF DWS Municipal Income Trust

DWS Municipal Income Trust is a closed-ended fixed income mutual fund launched and managed by Deutsche Investment Management Americas, Inc. The company invests in the fixed income markets of the United States. The fund invests in investment-grade tax-exempt municipal securities which are exempt from federal income tax. The fund benchmarks the performance of its portfolio against the Barclays Municipal Bond Index. The Fund invests in various states, such as Texas, Florida, Pennsylvania, Illinois, and California.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Share on Social Networks: